Show simple item record

dc.contributor.authorBae, S
dc.contributor.authorWong, H-L
dc.contributor.authorTie, J
dc.contributor.authorDesai, J
dc.contributor.authorField, K
dc.contributor.authorKosmider, S
dc.contributor.authorFourlanos, S
dc.contributor.authorJones, I
dc.contributor.authorSkinner, I
dc.contributor.authorGibbs, P
dc.date.accessioned2021-02-05T00:53:35Z
dc.date.available2021-02-05T00:53:35Z
dc.date.issued2015-01-01
dc.identifier.citationBae, S., Wong, H. -L., Tie, J., Desai, J., Field, K., Kosmider, S., Fourlanos, S., Jones, I., Skinner, I. & Gibbs, P. (2015). Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. JOURNAL OF CANCER EPIDEMIOLOGY, 2015, https://doi.org/10.1155/2015/189132.
dc.identifier.issn1687-8558
dc.identifier.urihttp://hdl.handle.net/11343/260195
dc.description.abstractDiabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal cancer patients treated and followed from 2000 to 2013 were analysed for baseline characteristics, treatment, and outcomes. 1116 patients with stage II colon cancer were identified, 55.5% were male and median age was 70.9 years (range 20.5-101.2). The diabetes patients (21.6%, n = 241) were older than nondiabetes patients (median 74.0 versus 69.6, p = 0.0001). There was no impact of diabetes on cancer presentation or pathology. Diabetes patients were less likely to receive adjuvant treatment (13.7 versus 24.8%, p = 0.002) but were equally likely to complete treatment (69.7 versus 67.7%, p = 1.00). Diabetes did not significantly impact cancer recurrence (HR = 1.07, 95% CI 0.71-1.63) or overall survival (HR = 1.23, 95% CI 0.88-1.72), adjusted for age. Diabetes medication did not impact cancer recurrence or survival. Cancer presentation and outcomes in diabetes patients are comparable to those of nondiabetes patients in those with stage II colon cancer. The effect of metformin merits further evaluation in patients with colon cancer.
dc.languageEnglish
dc.publisherHINDAWI LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleImpact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
dc.typeJournal Article
dc.identifier.doi10.1155/2015/189132
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.affiliation.departmentMedical Education
melbourne.affiliation.departmentSurgery (RMH)
melbourne.affiliation.departmentSurgery (Western Health)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleJournal of Cancer Epidemiology
melbourne.source.volume2015
dc.rights.licenseCC BY
melbourne.elementsid1038968
melbourne.contributor.authorJones, Ian
melbourne.contributor.authorGibbs, Peter
melbourne.contributor.authorDesai, Jayesh
melbourne.contributor.authorFourlanos, Spiros
melbourne.contributor.authorSkinner, Iain
melbourne.contributor.authorTie, Jeanne
melbourne.contributor.authorField, Kathryn
dc.identifier.eissn1687-8566
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record